Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (Mcrc): A phase II study with a safety lead-in cohort (The brave trial)
Ros Montañá, J., Roselló, S., Paez, D., Safont, M. J., Vidal, J., Gravalos, C., Polo, E., Jimenez-Fonseca, P., Gil Calle, … Read More
